Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Merck’s pharma is expected to decline due to shrinking sales of products such as Rebif, a multiple-sclerosis drug.

Matt Rourke/AP

Merck & Co. Inc. is in talks to acquire Cubist Pharmaceuticals Inc., a maker of antibiotics, in a deal valued at more than $7-billion, a person familiar with the matter said.

Merck would pay about $100 a share, and an agreement could be announced as early as this week, the person said yesterday. An offer in that range would represent a 34-per-cent premium over Cubist's closing share price on Dec. 5.

Cubist has said it plans to introduce four new drugs by 2020 to combat bacterial infections that are resistant to other treatments because of overuse. The rising threat of drug- resistant bugs has spurred public health authorities to urge companies to invest in new antibiotics, a field drugmakers had largely abandoned to focus on more profitable therapeutic areas such as cancer or hepatitis C.

Story continues below advertisement

Merck Chief Executive Officer Ken Frazier, 59, has said the second-biggest U.S. drugmaker was trying to make small to midsize acquisitions in areas that would complement its stable of treatments. The company wasn't interested in megadeals that are "very time consuming and distracting to what we're here to do, which is invest in new medicines," Frazier told Bloomberg News in July.

Steve Cragle, a spokesman for Whitehouse Station, New Jersey-based Merck, and Julie DiCarlo, a Cubist spokeswoman, didn't respond to requests for comment.

Merck had cash and equivalents of $14.3-billion at the end of September and total debt of $27.8-billion, according to data compiled by Bloomberg.

Cubicin, Cubist's top drug, was approved in 2003 by the U.S. Food and Drug Administration for serious skin infections. Its use was expanded in 2006 to include bloodstream infections. Cubicin generates more than 80 percent of Cubist's sales, which the Lexington, Massachusetts-based company has forecast will reach $2 billion by 2017.

Cubist's products may complement Merck's own infectious disease program. One of its experimental drugs, called relebactam, received fast-track status from the FDA in September, meaning the agency will accelerate the approval process. Relebactam works by inhibiting beta-lactamase, an enzyme produced by some bacteria that can cause resistance to widely used antibiotics, including penicillin.

Relebactam also received designation as a Qualified Infectious Disease Product, which would give it five extra years of market exclusivity when approved.

Merck also has an antibody targeting Clostridium difficile in a final-stage trial. Cubist already had a drug approved that works against the bacteria, which cause infectious diarrhea.

Story continues below advertisement

The U.S. Centers for Disease Control and Prevention has said antibiotic resistance is killing at least 23,000 Americans a year, making it "one of our most serious health threats."

Robert Perez, Cubist's president and chief operating officer, is scheduled to succeed Michael Bonney as chief executive officer on Jan. 1. Mr. Bonney has been CEO since June 2003.

Cubist surged as much as 26 per cent to $93.50 in after- hours U.S. trading on Dec. 5 before reaching $91.25. Merck climbed 0.9 percent to $61.49 at the close in New York.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies